In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI), with a price target of $30. The company’s shares opened today at $18.46.
White said:
“We base our $30 price target on probability-adjusted revenue forecasts for selinexor. We use a net present value of our revenue forecast through 2026, apply a 50% probability of success (POS) for selinexor in penta- refractory multiple myeloma, a 35% POS for selinexor in combination treatment for multiple myeloma, and a 25% POS for selinexor in DLBCL. We use a 4x P/S multiple and estimated YE18 fully diluted net cash of $2.20/ share. Our P/S multiple of 4x is in-line with Karyopharm’s peers that range between 2-5x.”
According to TipRanks.com, White is a 5-star analyst with an average return of 26.2% and a 56.5% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.
Karyopharm Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $26.75.
See today’s analyst top recommended stocks >>
Based on Karyopharm Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $33.66 million. In comparison, last year the company had a GAAP net loss of $29.39 million.
Based on the recent corporate insider activity of 62 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company, The engages in the discovery, development, and commercialization of drugs to treat cancer and other major diseases. The company intends to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
